GRFS - Grifols, S.A.
| Previous Close | 19.85 |
| Open | 20.31 |
| Bid | 20.12 x 3200 |
| Ask | 0.00 x 3000 |
| Day's Range | 20.30 - 20.59 |
| 52 Week Range | 17.42 - 23.03 |
| Volume | 2,335,598 |
| Avg. Volume | 1,636,976 |
| Market Cap | 18.512B |
| Beta (3Y Monthly) | 1.18 |
| PE Ratio (TTM) | 34.10 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.35 (1.77%) |
| Ex-Dividend Date | 2019-06-07 |
| 1y Target Est | N/A |
- PR Newswire
Grifols presents additional encouraging Alzheimer's trial results at AAIC
BARCELONA, Spain, July 16, 2019 /PRNewswire/ -- The Grifols Clinical Research team, led by Dr. Antonio Páez, today presented additional results of its AMBAR (Alzheimer Management by Albumin Replacement) clinical trial for the treatment of Alzheimer's at the Alzheimer's Association International Conference (AAIC) 2019 in Los Angeles (USA).
- PR Newswire
Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies
BARCELONA, Spain, July 4, 2019 /PRNewswire/ -- Grifols (GRF.MC) (GRF.P.MC) (GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify®, its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (FDA). Xembify® is used to treat primary immunodeficiencies.
- PR Newswire
Grifols Selected to Build Its First Intravenous Solutions Manufacturing Line in Africa
BARCELONA, Spain, July 3, 2019 /PRNewswire/ -- Grifols (GRF.MC) (GRF.P.MC) (GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced it has been selected by Soludia Maghreb, a provider of hemodialysis solutions headquartered in Morocco, as the main supplier for a new manufacturing plant in northern Africa. Grifols will develop, build and automate the main process equipment for the IV solutions line. Grifols Engineering, which provides technology and consultancy services to the pharmaceutical and biotech sectors, will design a state-of-the-art manufacturing line that will produce intravenous solutions bags. This is the first industrial project for Grifols on the African continent.
- PR Newswire
Grifols to launch plasma-protein-based bleeding-control solutions
BARCELONA, Spain, June 19, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that the VISTASEAL™ fibrin sealant will be the first product it will introduce with Ethicon Inc. as part of a broad global relationship to provide plasma-protein-based solutions to manage surgical bleeding. Grifols developed VISTASEAL™, which combines two plasma proteins, fibrinogen and thrombin, and is administered with Ethicon's airless spray device technology.
- PR Newswire
Grifols Announces PharmacyKeeper Bidirectional Integration with Epic
BARCELONA, Spain, April 30, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, announced today that its PharmacyKeeper Verification IV Workflow Management system now supports bidirectional integration with Epic.
- PR Newswire
Grifols Announces the Opening of its new Plasma Donor Center in Hinesville, Georgia
Investing $1.6 million into local community; set to employ over 40 people from the local area HINESVILLE, Ga. , April 29, 2019 /PRNewswire/ -- Grifols is pleased to announce the opening of a new Biotest ...
- PR Newswire
Grifols US donor centers exceed 250,000 pounds of food collected
- About 20% of children in the U.S. are frequently hungry while nearly 50 million Americans do not get enough to eat. RALEIGH, N.C., April 18, 2019 /PRNewswire/ -- Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its U.S. network of over 220 donor centers collaborated with local food banks and pantries to collect more than 250,000 pounds of groceries to help address food insecurity in local communities. According to Feeding America, a leading national hunger non-profit, the 253,000 pounds of food collected translates into 211,000i meals to help support the over 50,000 familiesii that cannot put sufficient food on the table.
- PR Newswire
Grifols donations of blood clotting factor helping people with hemophilia globally
- The company has donated more than 100 million international units (IUs) of blood clotting factor medicines globally during multi-year commitment to the WFH in developing regions. - Grifols creates Grifols Humanitarian Awards in Hemophilia to strengthen the global fight against the disease. BARCELONA, Spain, April 15, 2019 /PRNewswire/ -- Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its long-term global initiative to providing treatment to people with hemophilia in developing regions has surpassed 100 million international units (IUs) in donated blood clotting factor, a protein in blood that controls bleeding.
- PR Newswire
Grifols 2018 Annual Report on Form 20-F Filed With the SEC on April 5, 2019
BARCELONA, Spain , April 5, 2019 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced that it has filed its 2018 Annual Report on Form 20-F with the United ...
- PR Newswire
Grifols Announces the Opening of its new Plasma Donor Center in Russellville, AR
Investing $1.8 million into local community; set to employ over 40 people from the local area RUSSELLVILLE, Ark. , March 23, 2019 /PRNewswire/ -- Grifols is pleased to announce the opening of a new Biotest ...
- PR Newswire
Grifols PharmacyKeeper Receives KLAS Category Leader Award for Third Consecutive Year
This marks the third consecutive year the PharmacyKeeper Verification software has been recognized as the leader in the IV Workflow Management category by KLAS Research, a healthcare IT data and insight-gathering company that collects and publishes impartial research on the software and services used by healthcare providers and payers worldwide. The PharmacyKeeper suite of software applications was developed by MedKeeper, which was acquired by Grifols in January, 2018.
- PR Newswire
Grifols Receives FDA Approval for Procleix Babesia Assay for Donor Screening on Procleix Panther System
BARCELONA, Spain, Feb. 7, 2019 /PRNewswire/ -- Grifols, a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, announced today that the U.S. Food and Drug Administration (FDA) approved the Procleix Babesia assay, a qualitative assay for the detection of the ribosomal RNA from 4 Babesia species (B. microti, B. duncani, B. divergens, B. venatorum) in individual samples or up to 16 pooled lysed specimens from human donors, including donors of whole blood and blood components for transfusion.
- PR Newswire
Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe
- Grifols gains exclusive rights to fostamatinib in all potential indications in Europe and Turkey - Rigel to receive an upfront payment of $30 million , with the potential for $297.5 million in total ...
- PR Newswire
Grifols receives FDA approval of Erytra Eflexis®, the latest advancement in scalable blood typing solutions
- Erytra Eflexis is a fully automated, benchtop analyzer that performs pretransfusion compatibility testing - This system incorporates two laboratory configurations in a single instrument, providing laboratory ...
- PR Newswire
Grifols demonstrates a significant reduction (61%) in the progression of moderate Alzheimer's disease using its AMBAR treatment protocol
- AMBAR, an innovative treatment approach for Alzheimer's disease (AD) using plasma science has demonstrated, with statistical significance, the ability to slow down the progression of the disease in moderate AD patients. BARCELONA, Spain, Oct. 27, 2018 /PRNewswire/ -- Presenting the study results, Antonio Páez, M.D., Grifols Medical Director and Head of the AMBAR Clinical Program confirmed that the analysis of AMBAR data in moderate patients has shown positive, highly relevant results in a cohort of patients suffering from moderate Alzheimer's disease.
- PR Newswire
FDA Approves Grifols ID CORE XT Test For Molecular Red Blood Cell Typing
Test Offers Shortest Time to Reportable Results For US Hospitals, Reference Labs and Blood Centers - Efficient system analyzes 37 antigens of 10 blood group systems - Helps minimize allo-immunization risk ...
- PR Newswire
Grifols Delivers Promise of Advancing Plasma-derived Medicines through Innovative Vision and Donor Support
- Plasma-derived medicines replace missing or deficient proteins with healthy proteins that are obtained through human plasma donations. - Grifols' continued commitment to patients is evidenced by the expansion of its plasma donor center network and innovations for treatments of serious, rare and life-threatening illnesses. - Grifols is conducting clinical research on Alzheimer's disease.
- PR Newswire
Grifols Announces the Opening of Biotest Pharmaceuticals Corporation's Newest Plasma Donor Center in Bowling Green, Ohio
BOWLING GREEN, Ohio, Sept. 24, 2018 /PRNewswire/ -- Grifols is pleased to announce the opening of its newest Biotest Pharmaceuticals Corporation (BPC) plasma donor center located at 1616 East Wooster Street, Bowling Green, Ohio.